Cushing's Syndrome - Pipeline Review, H1 2018

Global Markets Direct’s, ‘Cushing's Syndrome - Pipeline Review, H1 2018’, provides an overview of the Cushing's Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cushing's Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cushing's Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cushing's Syndrome

The report reviews pipeline therapeutics for Cushing's Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cushing's Syndrome therapeutics and enlists all their major and minor projects

The report assesses Cushing's Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cushing's Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cushing's Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cushing's Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Cushing's Syndrome – Companies Involved in Therapeutics Development

Angion Biomedica Corp

Cushing's Syndrome – Companies Involved in Therapeutics Development

Angion Biomedica Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cushing's Syndrome – Overview

Cushing's Syndrome – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cushing's Syndrome – Overview

Cushing's Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Cushing's Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cushing's Syndrome – Companies Involved in Therapeutics Development

Angion Biomedica Corp

AstraZeneca Plc

Corcept Therapeutics Inc

Diurnal Group Plc

ElexoPharm GmbH

Hybrigenics SA

Millendo Therapeutics Inc

Novartis AG

Orphagen Pharmaceuticals Inc

Reset Therapeutics Inc

Strongbridge Biopharma plc

Cushing's Syndrome – Drug Profiles

ANG-3563 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing’s Syndrome and Cushing Disease – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-4017 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HBX-96819 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levoketoconazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nevanimibe hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

osilodrostat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relacorilant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit CYP11B1 for Cushing's Syndrome – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cushing Disease and Psychological Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cushing's Syndrome – Dormant Projects

Cushing's Syndrome – Product Development Milestones

Featured News & Press Releases

Apr 04, 2018: SteroTherapeutics Receives FDA Orphan-Drug Designation

Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's syndrome

Mar 20, 2018: Strongbridge Biopharma Announces Issuance of Patent for RECORLEV (levoketoconazole) for the Treatment of Cushing’s Syndrome

Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis

Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial

Jan 18, 2018: Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome

Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing’s Syndrome

Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome

Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017

Nov 02, 2016: Millendo Therapeutics to present data on ATR-101 program at Society for Endocrinology British Endocrine Societies Conference

May 31, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology

Apr 28, 2016: Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing’s Syndrome and Solid-Tumor Cancers

Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference

Dec 07, 2015: Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome

Oct 13, 2015: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development ...

List of Tables

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Cushing's Syndrome – Pipeline by Angion Biomedica Corp, H1 2018

Cushing's Syndrome – Pipeline by AstraZeneca Plc, H1 2018

Cushing's Syndrome – Pipeline by Corcept Therapeutics Inc, H1 2018

Cushing's Syndrome – Pipeline by Diurnal Group Plc, H1 2018

Cushing's Syndrome – Pipeline by ElexoPharm GmbH, H1 2018

Cushing's Syndrome – Pipeline by Hybrigenics SA, H1 2018

Cushing's Syndrome – Pipeline by Millendo Therapeutics Inc, H1 2018

Cushing's Syndrome – Pipeline by Novartis AG, H1 2018

Cushing's Syndrome – Pipeline by Orphagen Pharmaceuticals Inc, H1 2018

Cushing's Syndrome – Pipeline by Reset Therapeutics Inc, H1 2018

Cushing's Syndrome – Pipeline by Strongbridge Biopharma plc, H1 2018

Cushing's Syndrome – Dormant Projects, H1 2018

List of Figures

List of Figures

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products ...

List of Figures

Number of Products under Development for Cushing's Syndrome, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports